 Actinium Pharmaceuticals NYSEAMERICAN:ATNM was upgraded by Zacks Investment Research from a hold rating to a buy rating in a report released on Friday, Zacks.com reports. The firm currently has a 0.25 price objective on the biotechnology companys stock. Zacks Investment Researchs price objective would suggest a potential downside of 20.38 from the stocks previous close. ... 